Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05840835 |
| Title | Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (IMMINENT-01) |
| Acronym | IMMINENT-01 |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Immix Biopharma, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | child | senior |
| Covered Countries | BRA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| CIP Centro Integrado de Pesquisa / Hospital de Base / Fundação Faculdade de Medicina de São José do Rio Preto | RECRUITING | São José do Rio Preto | São Paulo | Brazil | Details | |
| Instituto do Cancer do Estado de São Paulo (ICESP) | RECRUITING | São Paulo | São Paulo | 01246-000 | Brazil | Details |